INSM
Insmed Incorporated
NMS
$103.45
-0.28
(-0.27%)
Pullback · -1.64σ
132-Day TAO Zones
21 EMA
+1 ATR
+2 ATR
−2 ATR
—
O —
H —
L —
C —
—
—
Key statistics
Mkt cap
$22.4B
P/E ttm
—
Fwd P/E
256.0
Beta
0.89
Day range
$103.45
52w range
$98.90 – $208.81
Avg vol
2.9M
RSI(2)
8.2
ROE
-294.5%
Net mgn
-144.4%
FCF mgn
-74.0%
Debt/Eq
1.05
Div yld
—
Sector
Healthcare
Industry
Biotechnology
Next earn
2026-08-06
Matrix setup grades
Long
—
score 14 · tech 14 / 80 · support 0 / 20
KC1 lower, -1.48 ATR from EMA21 · no notable pattern
- · KC1 lower stretch — light dip
- · Counter-trend long in breakout_down
Short
—
score 16 · tech 16 / 80 · support 0 / 20
below KC1 upper, -1.48 ATR from EMA21 · no notable pattern
- · Aligned with breakout_down (strong tailwind)
Options · swing
See more →
CALL
$105
2026-07-17
$7.65
PUT
$110
2026-07-17
$11.75
Insider activity
See more →No Form 4 filings in the last 30 days.
Earnings
See more →- Last reported
- 2026-05-07
- EPS (act / est)
- -0.76 / -1.00
- Surprise
- +23.9%
- Next report
- 2026-08-06
About
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a…